Skip to main content
Top
Published in: BMC Cancer 1/2021

Open Access 01-12-2021 | Urothelial Cancer | Research article

Comparative analysis of patients with upper urinary tract urothelial carcinoma in black-foot disease endemic and non-endemic area

Authors: Che-Wei Chang, Chien-Hui Ou, Chih-Chin Yu, Chi-Wen Lo, Chung-You Tsai, Pai-Yu Cheng, Yung-Tai Chen, Hsu-Che Huang, Chia-Chang Wu, Ching-Chia Li, Hsiang-Ying Lee

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Background

A high incidence of upper urinary tract urothelial carcinoma has been reported in the southwestern area of Taiwan, where arsenic water contamination was considered the main cause. However, there is no definite proof to show a correlation between arsenic water contamination and upper urinary tract urothelial carcinoma. To investigate the clinical and epidemiological features of patients with upper urinary tract urothelial carcinoma between arsenic water endemic and non-endemic areas, we analyzed patients in terms of characteristics, stratified overall survival, disease-free survival, and cancer-specific survival.

Methods

The records of a total of 1194 patients diagnosed with upper urinary tract urothelial carcinoma were retrospectively reviewed. Clinical data and current medical status were collected from the medical records. Statistical analyses were performed to determine the clinical variables and stratified survival curves between endemic and non-endemic groups.

Results

Female predominance was revealed in both endemic and non-endemic groups (male:female ratio = 1:1.2–1.4). No statistical differences were found in histological types, staging, and tumor size between the two groups. Nonetheless, patients with characteristics of aging and having end-stage renal disease were outnumbered in the non-endemic group, while a higher prevalence of previous bladder tumors and more ureteral tumors were found in the endemic group. Adjusted stratified cumulative survival curves suggested a poorer prognosis in endemic patients, especially in disease-free survival of early stage disease.

Conclusions

A higher mortality rate with more previous bladder cancer history and ureteral tumors was seen in patients with upper urinary tract urothelial carcinoma residing in the arsenic water contamination area. This may be attributed to the long-term carcinogenic effect of arsenic underground water.
Literature
1.
go back to reference Roupret M, et al. European association of urology guidelines on upper urinary tract Urothelial carcinoma: 2017 update. Eur Urol. 2018;73(1):111–22.CrossRef Roupret M, et al. European association of urology guidelines on upper urinary tract Urothelial carcinoma: 2017 update. Eur Urol. 2018;73(1):111–22.CrossRef
2.
go back to reference Nocks BN, et al. Transitional cell carcinoma of renal pelvis. Urology. 1982;19(5):472–7.CrossRef Nocks BN, et al. Transitional cell carcinoma of renal pelvis. Urology. 1982;19(5):472–7.CrossRef
3.
go back to reference Yang MH, et al. Unusually high incidence of upper urinary tract urothelial carcinoma in Taiwan. Urology. 2002;59(5):681–7.CrossRef Yang MH, et al. Unusually high incidence of upper urinary tract urothelial carcinoma in Taiwan. Urology. 2002;59(5):681–7.CrossRef
4.
go back to reference Chen CJ, et al. A retrospective study on malignant neoplasms of bladder, lung and liver in Blackfoot disease endemic area in Taiwan. Br J Cancer. 1986;53(3):399–405.CrossRef Chen CJ, et al. A retrospective study on malignant neoplasms of bladder, lung and liver in Blackfoot disease endemic area in Taiwan. Br J Cancer. 1986;53(3):399–405.CrossRef
5.
go back to reference Hopenhayn-Rich C, Biggs ML, Smith AH. Lung and kidney cancer mortality associated with arsenic in drinking water in Cordoba, Argentina. Int J Epidemiol. 1998;27(4):561–9.CrossRef Hopenhayn-Rich C, Biggs ML, Smith AH. Lung and kidney cancer mortality associated with arsenic in drinking water in Cordoba, Argentina. Int J Epidemiol. 1998;27(4):561–9.CrossRef
6.
go back to reference Kurttio P, et al. Arsenic concentrations in well water and risk of bladder and kidney cancer in Finland. Environ Health Perspect. 1999;107(9):705–10.CrossRef Kurttio P, et al. Arsenic concentrations in well water and risk of bladder and kidney cancer in Finland. Environ Health Perspect. 1999;107(9):705–10.CrossRef
7.
go back to reference Smith AH, et al. Lung, bladder, and kidney Cancer mortality 40 years after arsenic exposure reduction. J Natl Cancer Inst. 2018;110(3):241–9.CrossRef Smith AH, et al. Lung, bladder, and kidney Cancer mortality 40 years after arsenic exposure reduction. J Natl Cancer Inst. 2018;110(3):241–9.CrossRef
8.
go back to reference Chen CJ, et al. Malignant neoplasms among residents of a Blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res. 1985;45(11 Pt 2):5895–9.PubMed Chen CJ, et al. Malignant neoplasms among residents of a Blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res. 1985;45(11 Pt 2):5895–9.PubMed
9.
go back to reference Chiou HY, et al. Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8,102 residents in an arseniasis-endemic area in northeastern Taiwan. Am J Epidemiol. 2001;153(5):411–8.CrossRef Chiou HY, et al. Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8,102 residents in an arseniasis-endemic area in northeastern Taiwan. Am J Epidemiol. 2001;153(5):411–8.CrossRef
10.
go back to reference Wang YH, et al. Comparing the joint effect of arsenic exposure, cigarette smoking and risk genotypes of vascular endothelial growth factor on upper urinary tract urothelial carcinoma and bladder cancer. J Hazard Mater. 2013;262:1139–46.CrossRef Wang YH, et al. Comparing the joint effect of arsenic exposure, cigarette smoking and risk genotypes of vascular endothelial growth factor on upper urinary tract urothelial carcinoma and bladder cancer. J Hazard Mater. 2013;262:1139–46.CrossRef
11.
go back to reference Tan LB, Chen KT, Guo HR. Clinical and epidemiological features of patients with genitourinary tract tumour in a Blackfoot disease endemic area of Taiwan. BJU Int. 2008;102(1):48–54.CrossRef Tan LB, Chen KT, Guo HR. Clinical and epidemiological features of patients with genitourinary tract tumour in a Blackfoot disease endemic area of Taiwan. BJU Int. 2008;102(1):48–54.CrossRef
12.
go back to reference Mostofi FK, S.L., Torloni H., Histologic typing of urinary bladders. In Mostofi FK ed. International histological classification of tumors. . Geneva: WHO, 1973: p. 21–31. Mostofi FK, S.L., Torloni H., Histologic typing of urinary bladders. In Mostofi FK ed. International histological classification of tumors. . Geneva: WHO, 1973: p. 21–31.
13.
go back to reference In: Eble JN, S.G., Epstein JL, et al, eds, World Health Organization Classification of tumors. Pathology and Genetics: Tumours of the Urinary System and Male Genital Organs. Lyon. 2004: Lyon, France: IARCC Publishing;. In: Eble JN, S.G., Epstein JL, et al, eds, World Health Organization Classification of tumors. Pathology and Genetics: Tumours of the Urinary System and Male Genital Organs. Lyon. 2004: Lyon, France: IARCC Publishing;.
14.
go back to reference Cancer., A.J.C.o., AJCC Cancer Staging Handbook, 5th ed. Philadelphia: Lippincott-Raven Publishers, 1998. Cancer., A.J.C.o., AJCC Cancer Staging Handbook, 5th ed. Philadelphia: Lippincott-Raven Publishers, 1998.
15.
go back to reference Chen CH, et al. Clinicopathological characteristics and survival outcome of arsenic related bladder cancer in Taiwan. J Urol. 2009;181(2):547–52 discussion 553.CrossRef Chen CH, et al. Clinicopathological characteristics and survival outcome of arsenic related bladder cancer in Taiwan. J Urol. 2009;181(2):547–52 discussion 553.CrossRef
16.
go back to reference Munoz JJ, Ellison LM. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol. 2000;164(5):1523–5.CrossRef Munoz JJ, Ellison LM. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol. 2000;164(5):1523–5.CrossRef
17.
go back to reference Ozsahin M, et al. Prognostic factors in urothelial renal pelvis and ureter tumours: a multicentre rare Cancer network study. Eur J Cancer. 1999;35(5):738–43.CrossRef Ozsahin M, et al. Prognostic factors in urothelial renal pelvis and ureter tumours: a multicentre rare Cancer network study. Eur J Cancer. 1999;35(5):738–43.CrossRef
18.
go back to reference Raman JD, et al. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973-2005. BJU Int. 2011;107(7):1059–64.CrossRef Raman JD, et al. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973-2005. BJU Int. 2011;107(7):1059–64.CrossRef
19.
go back to reference Chou YH, Huang CH. Unusual clinical presentation of upper urothelial carcinoma in Taiwan. Cancer. 1999;85(6):1342–4.CrossRef Chou YH, Huang CH. Unusual clinical presentation of upper urothelial carcinoma in Taiwan. Cancer. 1999;85(6):1342–4.CrossRef
20.
go back to reference Favaretto RL, et al. The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol. 2010;58(4):574–80.CrossRef Favaretto RL, et al. The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol. 2010;58(4):574–80.CrossRef
21.
go back to reference Shariat SF, et al. Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol. 2011;29(4):481–6.CrossRef Shariat SF, et al. Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol. 2011;29(4):481–6.CrossRef
22.
go back to reference Ouzzane A, et al. Epidemiology and risk factors of upper urinary tract tumors: literature review for the yearly scientific report of the French National Association of urology. Prog Urol. 2014;24(15):966–76.CrossRef Ouzzane A, et al. Epidemiology and risk factors of upper urinary tract tumors: literature review for the yearly scientific report of the French National Association of urology. Prog Urol. 2014;24(15):966–76.CrossRef
23.
go back to reference Wen CP, et al. Smoking behaviour in Taiwan, 2001. Tob Control. 2005;14(Suppl 1):i51–5.CrossRef Wen CP, et al. Smoking behaviour in Taiwan, 2001. Tob Control. 2005;14(Suppl 1):i51–5.CrossRef
24.
go back to reference Wang SM, et al. Increased upper and lower tract urothelial carcinoma in patients with end-stage renal disease: a nationwide cohort study in Taiwan during 1997-2008. Biomed Res Int. 2014;2014:149750.PubMedPubMedCentral Wang SM, et al. Increased upper and lower tract urothelial carcinoma in patients with end-stage renal disease: a nationwide cohort study in Taiwan during 1997-2008. Biomed Res Int. 2014;2014:149750.PubMedPubMedCentral
25.
go back to reference Li CC, et al. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. Eur Urol. 2008;54(5):1127–34.CrossRef Li CC, et al. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. Eur Urol. 2008;54(5):1127–34.CrossRef
26.
go back to reference Lamm SH, et al. Arsenic cancer risk confounder in Southwest Taiwan data set. Environ Health Perspect. 2006;114(7):1077–82.CrossRef Lamm SH, et al. Arsenic cancer risk confounder in Southwest Taiwan data set. Environ Health Perspect. 2006;114(7):1077–82.CrossRef
27.
go back to reference Schoen A, et al. Arsenic toxicity at low doses: epidemiological and mode of action considerations. Toxicol Appl Pharmacol. 2004;198(3):253–67.CrossRef Schoen A, et al. Arsenic toxicity at low doses: epidemiological and mode of action considerations. Toxicol Appl Pharmacol. 2004;198(3):253–67.CrossRef
28.
go back to reference Petrick JS, et al. Monomethylarsonous acid (MMA (III)) is more toxic than arsenite in Chang human hepatocytes. Toxicol Appl Pharmacol. 2000;163(2):203–7.CrossRef Petrick JS, et al. Monomethylarsonous acid (MMA (III)) is more toxic than arsenite in Chang human hepatocytes. Toxicol Appl Pharmacol. 2000;163(2):203–7.CrossRef
29.
go back to reference Cohen SM, et al. Arsenic-induced bladder cancer in an animal model. Toxicol Appl Pharmacol. 2007;222(3):258–63 s.CrossRef Cohen SM, et al. Arsenic-induced bladder cancer in an animal model. Toxicol Appl Pharmacol. 2007;222(3):258–63 s.CrossRef
30.
go back to reference Medeiros M, et al. Expression of selected pathway-marker genes in human Urothelial cells exposed chronically to a non-cytotoxic concentration of Monomethylarsonous acid. Toxicol Rep. 2014;1:421–34.CrossRef Medeiros M, et al. Expression of selected pathway-marker genes in human Urothelial cells exposed chronically to a non-cytotoxic concentration of Monomethylarsonous acid. Toxicol Rep. 2014;1:421–34.CrossRef
Metadata
Title
Comparative analysis of patients with upper urinary tract urothelial carcinoma in black-foot disease endemic and non-endemic area
Authors
Che-Wei Chang
Chien-Hui Ou
Chih-Chin Yu
Chi-Wen Lo
Chung-You Tsai
Pai-Yu Cheng
Yung-Tai Chen
Hsu-Che Huang
Chia-Chang Wu
Ching-Chia Li
Hsiang-Ying Lee
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-07799-4

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine